Abstract
Atopic dermatitis (AD) is a common skin condition characterized by inflammation that presents with erythematous and pruritic skin. Its chronic relapse-remitting nature has a significant impact on the quality of life, and often requires ongoing management. Given the limited treatments available for AD, there remains a large need for effective and safe alternative therapies for long-term use. Janus kinase (JAK) inhibitors are a new class of agents that target the JAK-STAT pathway, which plays an important role in the production of proinflammatory cytokines involved in AD pathogenesis. Phase II and III clinical trials revealed that JAK inhibitors, such as upadacitinib, are effective and well-tolerated agents for the treatment of moderate-to-severe AD. As a result, upadacitinib was approved for use in patients with moderate-to-severe AD by the European Medicines Agency (2021), Health Canada (2021) and the FDA (2022) in the last year. It is important for dermatologists to be aware of the clinical evidence to continue incorporating the use of upadacitinib into the treatment algorithm for AD, which will ultimately lead to improved patient outcomes. Therefore, this review is an up-to-date summary of the clinical data available on the efficacy and safety of upadacitinib treatment for AD.
Reference63 articles.
1. Deckers, I.A., McLean, S., Linssen, S., Mommers, M., van Schayck, C.P., and Sheikh, A. Investigigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: A systematic review of epidemiological studies. PLoS ONE, 2012. 7.
2. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions;Hay;J. Investig. Dermatol.,2014
3. Atopic dermatitis;Bieber;N. Engl. J. Med.,2008
4. Increased Risk of Cutaneous and Systemic Infections in Atopic Dermatitis-A Cohort Study;Langan;J. Investig. Dermatol.,2017
5. Current aspects of innate and adaptive immunity in atopic dermatitis;Wollenberg;Clin. Rev. Allergy Immunol.,2007
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献